- Home
- UTL vs EYPT Comparison
UTL vs EYPT Comparison
Compare UTL & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTL
- EYPT
- Stock Information
- Founded
- UTL 1984
- EYPT N/A
- Country
- UTL United States
- EYPT
- Employees
- UTL N/A
- EYPT N/A
- Industry
- UTL Power Generation
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- UTL Utilities
- EYPT Industrials
- Exchange
- UTL Nasdaq
- EYPT Nasdaq
- Market Cap
- UTL 856.6M
- EYPT 741.0M
- IPO Year
- UTL N/A
- EYPT N/A
- Fundamental
- Price
- UTL $46.22
- EYPT $14.01
- Analyst Decision
- UTL Hold
- EYPT
- Analyst Count
- UTL 1
- EYPT 0
- Target Price
- UTL $55.00
- EYPT N/A
- AVG Volume (30 Days)
- UTL 129.3K
- EYPT 659.8K
- Earning Date
- UTL 11-03-2025
- EYPT 08-06-2025
- Dividend Yield
- UTL 3.90%
- EYPT N/A
- EPS Growth
- UTL N/A
- EYPT N/A
- EPS
- UTL 2.91
- EYPT N/A
- Revenue
- UTL $493,800,000.00
- EYPT $51,898,000.00
- Revenue This Year
- UTL $7.06
- EYPT N/A
- Revenue Next Year
- UTL $7.63
- EYPT N/A
- P/E Ratio
- UTL $15.88
- EYPT N/A
- Revenue Growth
- UTL N/A
- EYPT 2.99
- 52 Week Low
- UTL $45.11
- EYPT $3.91
- 52 Week High
- UTL $63.52
- EYPT $14.37
- Technical
- Relative Strength Index (RSI)
- UTL 38.92
- EYPT 77.25
- Support Level
- UTL $45.11
- EYPT $11.38
- Resistance Level
- UTL $47.89
- EYPT $12.24
- Average True Range (ATR)
- UTL 0.96
- EYPT 0.74
- MACD
- UTL -0.04
- EYPT 0.13
- Stochastic Oscillator
- UTL 31.01
- EYPT 89.80
About UTL UNITIL Corporation
Unitil Corp is a holding company, through its subsidiaries it is engaged in the local distribution of electricity and natural gas throughout its service territories in the states of New Hampshire, Massachusetts, and Maine. The Company has two operating and reportable segments: Utility Electric Operations and Utility Gas Operations. Majority of revenue is gained from Electric Segment.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.